|1.||Herz, Joachim: 2 articles (10/2014 - 09/2014)|
|2.||Shaul, Philip W: 2 articles (10/2014 - 09/2014)|
|3.||Mineo, Chieko: 2 articles (10/2014 - 09/2014)|
|4.||Konaniah, Eddy S: 2 articles (10/2014 - 09/2014)|
|5.||Ulrich, Victoria: 2 articles (10/2014 - 09/2014)|
|6.||Hui, David Y: 2 articles (10/2014 - 09/2014)|
|7.||Khadka, Sadiksha: 1 article (10/2014)|
|8.||Lee, Wan-Ru: 1 article (10/2014)|
|9.||Salmon, Jane E: 1 article (10/2014)|
|10.||Shen, Yu-Min: 1 article (10/2014)|
02/01/2009 - "Our group has previously reported genetic studies associating polymorphisms in the low density lipoprotein receptor related protein 8 (LRP8) gene with myocardial infarction. "
01/01/2009 - "The R952Q variant in the low density lipoprotein receptor-related protein 8 (LRP8)/apolipoprotein E receptor 2 (ApoER2) gene has been recently associated with familial and premature myocardial infarction (MI) by means of genome-wide linkage scan/association studies. "
|2.||Alzheimer Disease (Alzheimer's Disease)
01/01/2010 - "Polymorphisms in the human apolipoprotein E receptor 2 gene in Japanese sporadic Alzheimer's disease patients."
11/08/2002 - "Previous studies had shown association of LDL receptor-related protein (LRP) and AD, therefore we speculated that another member of this LDL receptor family, LRP8 (also called apolipoprotein E receptor 2 or ApoER2), which is predominantly expressed in brain, might be associated with Alzheimer's disease. "
11/08/2002 - "Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease."
09/01/2010 - "PCSK9 has also been shown to regulate the levels of additional membrane-bound proteins in vitro, including the very low-density lipoprotein receptor (VLDLR), apolipoprotein E receptor 2 (ApoER2) and the beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1), which are all highly expressed in the CNS and have been implicated in Alzheimer's disease. "
|3.||Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome)
10/01/2014 - "The initiating process entails NO deficiency mediated by β2-glycoprotein I recognition by aPLs and apolipoprotein E receptor 2. The modulation of endothelial apolipoprotein E receptor 2 function or NO bioavailability may represent new interventions to prevent the nonthrombotic vascular occlusion and resulting cardiovascular disorders that afflict antiphospholipid syndrome patients."
01/27/2011 - "Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome."
08/01/2008 - "Previous work has shown that binding of dimeric beta(2)-GPI to the platelet receptors apolipoprotein E receptor 2' (ApoER2') and glycoprotein Ibalpha (GPIbalpha) mediates increased platelet activation in an in vitro thrombosis model. "
01/27/2011 - "We investigated the role of Apolipoprotein E receptor 2 (ApoER2') on the pathogenic effects of a patient-derived polyclonal aPL IgG preparation (IgG-APS), a murine anti-β(2)GPI monoclonal antibody (E7) and of a constructed dimeric β(2)GPI I (dimer), which in vitro mimics β(2)GPI-antibody immune complexes, using an animal model of thrombosis, and ApoER2-deficient (-/-) mice. "
10/01/2014 - "Further experiments showed that aPL antagonism of endothelial migration and repair is mediated by antibody recognition of β2-glycoprotein I, apolipoprotein E receptor 2, and a decline in bioavailable NO. Consistent with these mechanisms, the adverse impacts of aPLs on reendothelialization and neointima formation were fully prevented by the NO donor molsidomine. "
|1.||apolipoprotein E receptor 2 (low density lipoprotein receptor-related protein 8)
|2.||LDL Receptors (LDL Receptor)
|3.||LDL-Receptor Related Protein 1 (LDL-Receptor Related Protein)
|4.||Apolipoproteins E (ApoE)
|7.||Proteins (Proteins, Gene)
|8.||Molsidomine (SIN 10)
|9.||Immunoglobulin G (IgG)